Drug Topics
SEPTEMBER 25, 2024
Pharmacy professionals are at an increased risk of substance abuse due to many factors, but long-term recovery can be achieved with the help of specialized recovery networks.
STAT
SEPTEMBER 25, 2024
Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths. The decision is a stunning blow for a drug that was approved in 2019 , heralded as a new way to treat the inherited blood disorder. Pfizer acquired the maker of Oxbryta, a biotech company called Global Blood Therapeutics, in 2022 for $5.4 billion.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
SEPTEMBER 25, 2024
Additional education can address ambivalence for patients and providers, which can start at the pharmacist level, as they are essential sources of information for patients.
STAT
SEPTEMBER 25, 2024
Recent headlines about a potent new immunotherapy have mostly focused on the U.S. company helping to develop it. Less attention has been paid to Akeso, a Chinese biotech that had kept a low profile until its drug bested Merck’s mega-blockbuster Keytruda in a late-stage lung cancer trial. Now, Akeso’s leaders want you to know that its recent success isn’t a one-off.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
SEPTEMBER 25, 2024
The approval comes shortly after the FDA approved arimoclomol from Zevra Therapeutics to treat neurological manifestations of the disease in combination with miglustat.
STAT
SEPTEMBER 25, 2024
Usually, introductory meetings with startup executives are perfunctory and fade to irrelevance within an hour. But I still remember the first moment I met 23andMe CEO and co-founder Anne Wojcicki in 2007. My editor at the time had set up a meeting between my reporting partner and I and Wojcicki, along with 23andMe co-founder Linda Avey, at an upscale sandwich shop on East 13th Street in New York City.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
SEPTEMBER 25, 2024
People taking semaglutide medications like Ozempic for diabetes may be at reduced risk of drug overdose, according to new research. Prescriptions for semaglutide, which includes Ozempic and Rybelsus, were linked to lower overdose rates among patients with type 2 diabetes who were also diagnosed with opioid use disorder, according to a paper published Wednesday.
Fierce Pharma
SEPTEMBER 25, 2024
Pfizer will voluntarily pull its sickle cell disease drug Oxbryta from all markets worldwide, a major blow to a $5.4 billion acquisition the New York pharma made two years ago. | Pfizer will voluntarily pull its sickle cell disease drug Oxbryta from all markets worldwide, a major blow to its $5.4 billion acquisition of Global Blood Therapeutics two years ago.
STAT
SEPTEMBER 25, 2024
Prostate cancer presents a tricky screening challenge. Catching it early could mean dodging a painful journey with advanced cancer. Yet a sizable majority of prostate cancers are “indolent” — slow growing tumors that most likely would never metastasize during the patient’s lifetime, and whose treatment would do more harm than good.
Drug Topics
SEPTEMBER 25, 2024
In an installment of Drug Topics’ 5 Questions With a Pharmacist, Henry and Jade Ranger of The Prescription Shoppe in Williamsburg, Virginia, discussed their practice and what it’s like operating a business together.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
SEPTEMBER 25, 2024
Moderna was scolded by a U.K. trade group over a WhatsApp message that offered children a hefty $2,000 for participating in a clinical trial of its Covid-19 booster vaccine. The trial, which was called NextCOVE, recruited adults and children age 12 and older in a number of locations last year around the U.K., the U.S. and Canada. A pediatrician, who worked at an unnamed hospital in the U.K., posted the message in hopes of soliciting participants, mentioned the amount of money involved, and close
Drug Topics
SEPTEMBER 25, 2024
Higher doses of buprenorphine may also be more effective against the increasing prevalence of fentanyl in the opioid crisis.
STAT
SEPTEMBER 25, 2024
Celldex Therapeutics reported Wednesday that its experimental medicine for a condition that causes chronic hives reduced hive activity in patients, completely clearing it in some. However, there was a high rate of patient discontinuations in the trial, due in part to side effects including changes in hair color. Those concerns sent Celldex shares down more than 20% following the company’s announcement.
pharmaphorum
SEPTEMBER 25, 2024
Novo Nordisk chief executive Lars Fruergaard Jørgensen was taken to task by US lawmakers over the price of the company's semaglutide drugs for diabetes and obesity at a congressional hearing yesterday – but would not commit to reducing them. Jørgensen danced around the topic of price cuts, saying Novo Nordisk supported "anything that helps patients get access and affordability […] we will look into.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
SEPTEMBER 25, 2024
WASHINGTON — The trade association for generic drugs and biosimilars has chosen a new leader: John Murphy. Four sources familiar with the decision said Murphy will be named as the new head of the Association for Accessible Medicines. AAM declined to comment on the CEO selection, but a spokesperson for the group said it will make an announcement later Wednesday.
Fierce Healthcare
SEPTEMBER 25, 2024
Recent survey and system data are again suggesting that payers’ increasing claims denials are a pain point for healthcare providers. | A new revenue cycle leadership survey from Experian Health, monthly dashboard updates from Kodiak Solutions and other recent commentary paint a picture of more demanding payers.
STAT
SEPTEMBER 25, 2024
Over the three decades that I have worked in animal health, I have borne witness to the mounting effects of antimicrobial resistance (AMR) in animals. Just like in people, while bacterial infections in animals were once predictably treatable with routine antimicrobials, we now face resistant infections that make it harder to treat animals. Then we end up on a slippery slope of needing to use newer antimicrobials, helping to treat the infection but adding risks for development of even more resist
Drug Topics
SEPTEMBER 25, 2024
Catch up on important immunization news from the month of September.
STAT
SEPTEMBER 25, 2024
On July 1st, 1995, the world’s spotlight shone upon Yale’s football stadium in New Haven, Connecticut. It was the latest Special Olympics World Games, and the organizers had lined up big-name musicians like Hootie & the Blowfish and Boyz II Men for the opening ceremony. United States President Bill Clinton and First Lady Hillary Clinton even made an appearance.
pharmaphorum
SEPTEMBER 25, 2024
Aurion Biotech has launched its cell therapy Vyznova for serious eye disorder bullous keratopathy in Japan, its debut market, becoming an alternative to corneal replacement using donor tissue.Vyznova (neltependocel, formerly AURN001) is the world's first allogeneic cell therapy for corneal endothelial disease, according to the Seattle, Washington-based company.
Pharmacy Times
SEPTEMBER 25, 2024
Artificial intelligence shows promise in improving diagnosis and treatment for patients with multiple myeloma.
pharmaphorum
SEPTEMBER 25, 2024
Pfizer is voluntarily withdrawing its sickle cell drug Oxbryta after a review revealed an imbalance of deaths in clinical trials
STAT
SEPTEMBER 25, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Which CEO drank out of my colleague Matt Herper’s glass of water? Read on today to find out!
pharmaphorum
SEPTEMBER 25, 2024
Flagship Pioneering-backed artificial intelligence startup Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis.The wide-ranging deal, worth up to $1 billion, covers multiple targets and disease areas and focuses on the discovery and development of protein-based therapeutics using Generate's generative AI (genAI) platform.
Fierce Pharma
SEPTEMBER 25, 2024
As private equity firms reportedly place their bids, Sanofi may soon follow in the footsteps of GSK and Johnson & Johnson with the separation of its consumer health unit. | Sanofi has received two private equity offers for its consumer health business, which could be valued at 15 billion euros ($16.7 billion) or more, Bloomberg reported Tuesday, citing people close to the matter.
STAT
SEPTEMBER 25, 2024
Hello, everyone, and how are you today? We are doing just fine, thank you, and given that the middle of the week is here, we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy. So we are digging about the pantry and firing up our coffee kettle to get things started.
Fierce Pharma
SEPTEMBER 25, 2024
Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma has hit a major setback. Bristol and its partner 2seventy bio have decided to pull the plug on the phase 3 KarMMa-9 trial in first-line myeloma after struggling to enroll patients.
Pharmacy Times
SEPTEMBER 25, 2024
Although Madabhushi said there are emerging tools for clinical decision support, he said there is a greater need for tools further downstream in the post-diagnosis stages.
Fierce Pharma
SEPTEMBER 25, 2024
While it was just last week that Zevra Therapeutics’ Miplyffa became the first FDA-approved treatment for the lysosomal storage disorder Niemann-Pick disease type C (NPC), IntraBio has already one- | While it was just last week that Zevra Therapeutics’ Miplyffa became the first FDA-approved treatment for the lysosomal storage disorder Niemann-Pick disease type C, IntraBio has already one-upped its rare disease rival.
Pharmacy Times
SEPTEMBER 25, 2024
Early diagnosis of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) may mitigate progression.
Fierce Pharma
SEPTEMBER 25, 2024
Three months after Amgen revealed that Uplizna had aced a phase 3 trial in immunoglobulin G4-related disease (IgG4), the company said the anti-CD-19 antibody has excelled in a study against another | Three months after Amgen revealed that Uplizna had aced a phase 3 trial in IgG4, the company said the anti-CD-19 antibody has excelled in a study against another neurologic disorder, myasthenia gravis.
Fierce Healthcare
SEPTEMBER 25, 2024
Startup Medicare Advantage insurer Zing Health banked a $140 million funding round it intends to use to enhance its special needs plans. | Startup Medicare Advantage insurer Zing Health banked a $140 million funding round it intends to use to enhance its special needs plans.
The Guardian - Pharmaceutical Industry
SEPTEMBER 25, 2024
Closure of hundreds of outlets hitting rural areas, older people and deprived communities hardest, according to Healthwatch England High street pharmacies are closing at such an alarming rate that it threatens the drive to use them instead of GPs to care for millions of people, the NHS’s patient champion warns today. A total of 436 community pharmacies in England shut permanently last year and there were also 13,863 temporary closures, which stopped patients from obtaining health advice and medi
pharmaphorum
SEPTEMBER 25, 2024
Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug
Expert insights. Personalized for you.
201 
Let's personalize your content